Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.
Thirty-nine patients with uncomplicated gonorrhea were randomized to receive single, oral 50-, 100-, or 200-mg doses of trovafloxacin (CP-99,219), a new quinolone antibiotic. All 31 evaluable patients were cured of infection. Trovafloxacin was well tolerated. The trovafloxacin MICs at which 50 and 90% of 36 Neisseria gonorrhoeae isolates are inhibited were 0.002 and 0.004 mg/liter, respectively (MIC range, < 0.0005 to 0.008 mg/liter). These preliminary studies suggest that trovafloxacin is effective for the treatment of uncomplicated gonorrhea at single oral doses as low as 50 mg.
Hook
E W
EW
Department of Medicine, University of Alabama at Birmingham, USA. ehook@uabid.dom.uab.edu
Pinson
G B
GB
Blalock
C J
CJ
Johnson
R B
RB
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D024841:Fluoroquinolones; D006069:Gonorrhea / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009287:Naphthyridines / Q000627:therapeutic use*; D009344:Neisseria gonorrhoeae / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C080163:trovafloxacin